MicroRNA expression and its clinical implications in Ewing's sarcoma

Cell Proliferation

Volumn 48, Issue 1, 2015, Pages 1-6

  Li, Zheng ^a   Yu, Xin ^a   Shen, Jianxiong ^a   Wu, William Ka Kei ^b   Chan, Matthew T V ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SCREENING; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL INVASION; EWING SARCOMA; GENE EXPRESSION; HUMAN; METASTASIS; NONHUMAN; PATHOGENESIS; TREATMENT RESPONSE; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; PROGNOSIS; SARCOMA, EWING; SIGNAL TRANSDUCTION;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PROGNOSIS; SARCOMA, EWING; SIGNAL TRANSDUCTION;

EID: 84920918458     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/cpr.12160     Document Type: Article

References (54)

1. Fleuren ED, Versleijen-Jonkers YM, Boerman OC, van der Graaf WT (2014) Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives. Biochim. Biophys. Acta 1845, 266-276.
2. Ahmed AA, Zia H, Wagner L (2014) Therapy resistance mechanisms in Ewing's sarcoma family tumors. Cancer Chemother. Pharmacol. 73, 657-663.
3. Lewin J, Wieringa S, Collins M, Desai J, Orme L, Lingaratnam S et al. (2013) Intra-patient dose escalation in Ewing's sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review. Clin. Sarcoma Res. 3, 15.
4. Sasaki T, Onishi T, Yabana T, Hoshina A (2013) Ewing's sarcoma/primitive neuroectodermal tumor arising from the adrenal gland: a case report and literature review. Tumori 99, e104-e106.
5. Ross KA, Smyth NA, Murawski CD, Kennedy JG (2013) The biology of ewing sarcoma. ISRN Oncol. 2013, 759725.
6. Amaral AT, Ordonez JL, Otero-Motta AP, Garcia-Dominguez DJ, Sevillano MV, de Alava E (2014) Innovative therapies in Ewing Sarcoma. Adv. Anat. Pathol. 21, 44-62.
7. Todorova R (2014) Ewing's sarcoma cancer stem cell targeted therapy. Curr. Stem Cell Res. Ther. 9, 46-62.
8. Zhang WH, Gui JH, Wang CZ, Chang Q, Xu SP, Cai CH et al. (2012) The identification of miR-375 as a potential biomarker in distal gastric adenocarcinoma. Oncol. Res. 20, 139-147.
9. Zhou J, Song S, Cen J, Zhu D, Li D, Zhang Z (2012) MicroRNA-375 is downregulated in pancreatic cancer and inhibits cell proliferation in vitro. Oncol. Res. 20, 197-203.
10. Misawa A, Katayama R, Koike S, Tomida A, Watanabe T, Fujita N (2010) AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells. Oncol. Res. 19, 23-33.
11. Wang Z, Yin B, Wang B, Ma Z, Liu W, Lv G (2014) MicroRNA-210 promotes proliferation and invasion of peripheral nerve sheath tumor cells targeting EFNA3. Oncol. Res. 21, 145-154.
12. Xiao X, Tang C, Xiao S, Fu C, Yu P (2013) Enhancement of proliferation and invasion by MicroRNA-590-5p via targeting PBRM1 in clear cell renal carcinoma cells. Oncol. Res. 20, 537-544.
13. Ye Z, Jingzhong L, Yangbo L, Lei C, Jiandong Y (2014) Propofol inhibits proliferation and invasion of osteosarcoma cells by regulation of microRNA-143 expression. Oncol. Res. 21, 201-207.
14. Yu X, Li Z, Shen J, Wu WK, Liang J, Weng X et al. (2013) MicroRNA-10b promotes nucleus pulposus cell proliferation through RhoC-Akt pathway by targeting HOXD10 in intervetebral disc degeneration. PLoS One 8, e83080.
15. Kaufman EJ, Miska EA (2010) The microRNAs of Caenorhabditis elegans. Semin. Cell Dev. Biol. 21, 728-737.
16. Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L et al. (2009) MicroRNA profiling of human gastric cancer. Mol. Med. Rep. 2, 963-970.
17. Dassow H, Aigner A (2013) MicroRNAs (miRNAs) in colorectal cancer: from aberrant expression towards therapy. Curr. Pharm. Des. 19, 1242-1252.
18. Marcinkowska M, Szymanski M, Krzyzosiak WJ, Kozlowski P (2011) Copy number variation of microRNA genes in the human genome. BMC Genom. 12, 183.
19. Papagiannakopoulos T, Kosik KS (2008) MicroRNAs: regulators of oncogenesis and stemness. BMC Med. 6, 15.
20. Sato F, Tsuchiya S, Meltzer SJ, Shimizu K (2011) MicroRNAs and epigenetics. FEBS J. 278, 1598-1609.
21. Chen Z, Wu J, Yang C, Fan P, Balazs L, Jiao Y et al. (2012) DiGeorge syndrome critical region 8 (DGCR8) protein-mediated microRNA biogenesis is essential for vascular smooth muscle cell development in mice. J. Biol. Chem. 287, 19018-19028.
22. Han L, Witmer PD, Casey E, Valle D, Sukumar S (2007) DNA methylation regulates MicroRNA expression. Cancer Biol. Ther. 6, 1284-1288.
23. Nelson KM, Weiss GJ (2008) MicroRNAs and cancer: past, present, and potential future. Mol. Cancer Ther. 7, 3655-3660.
24. Fan P, Chen Z, Tian P, Liu W, Jiao Y, Xue Y et al. (2013) miRNA biogenesis enzyme Drosha is required for vascular smooth muscle cell survival. PLoS One 8, e60888.
25. Fernandez-Hernando C, Ramirez CM, Goedeke L, Suarez Y (2013) MicroRNAs in metabolic disease. Arterioscler. Thromb. Vasc. Biol. 33, 178-185.
26. Grant JS, White K, Maclean MR, Baker AH (2013) MicroRNAs in pulmonary arterial remodeling. Cell. Mol. Life Sci. 70, 4479-4494.
27. Guancial EA, Bellmunt J, Yeh S, Rosenberg JE, Berman DM (2014) The evolving understanding of microRNA in bladder cancer. Urol. Oncol. 32, 41. e31-e40.
28. Rottiers V, Naar AM (2012) MicroRNAs in metabolism and metabolic disorders. Nat. Rev. Mol. Cell Biol. 13, 239-250.
29. Li Z, Lei H, Luo M, Wang Y, Dong L, Ma Y et al. (2015) DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer 18, 43-54.
30. Wu W, He X, Kong J, Ye B (2012) Mir-373 affects human lung cancer cells' growth and its E-cadherin expression. Oncol. Res. 20, 163-170.
31. Kim BM, Woo J, Kanellopoulou C, Shivdasani RA (2011) Regulation of mouse stomach development and Barx1 expression by specific microRNAs. Development 138, 1081-1086.
32. Perri R, Nares S, Zhang S, Barros SP, Offenbacher S (2012) MicroRNA modulation in obesity and periodontitis. J. Dent. Res. 91, 33-38.
33. Wheeler G, Ntounia-Fousara S, Granda B, Rathjen T, Dalmay T (2006) Identification of new central nervous system specific mouse microRNAs. FEBS Lett. 580, 2195-2200.
34. Wilfred BR, Wang WX, Nelson PT (2007) Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol. Genet. Metab. 91, 209-217.
35. Bou Kheir T, Futoma-Kazmierczak E, Jacobsen A, Krogh A, Bardram L, Hother C et al. (2011) miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol. Cancer 10, 29.
36. Du B, Wang Z, Zhang X, Feng S, Wang G, He J et al. (2014) MicroRNA-545 suppresses cell proliferation by targeting cyclin D1 and CDK4 in lung cancer cells. PLoS One 9, e88022.
37. Duan Z, Choy E, Harmon D, Liu X, Susa M, Mankin H et al. (2011) MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. Mol. Cancer Ther. 10, 1337-1345.
38. Fei X, Qi M, Wu B, Song Y, Wang Y, Li T (2012) MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression. FEBS Lett. 586, 392-397.
39. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J (2010) miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 31, 766-776.
40. Ma L (2010) Role of miR-10b in breast cancer metastasis. Breast Cancer Res. 12, 210.
41. Zhang Z, Huang L, Yu Z, Chen X, Yang D, Zhan P et al. (2014) Let-7a functions as a tumor suppressor in Ewing's sarcoma cell lines partly by targeting cyclin-dependent kinase 6. DNA Cell Biol. 33, 136-147.
42. Karnuth B, Dedy N, Spieker T, Lawlor ER, Gattenlohner S, Ranft A et al. (2014) Differentially expressed miRNAs in Ewing sarcoma compared to mesenchymal stem cells: low miR-31 expression with effects on proliferation and invasion. PLoS One 9, e93067.
43. Mosakhani N, Guled M, Leen G, Calabuig-Farinas S, Niini T, Machado I et al. (2012) An integrated analysis of miRNA and gene copy numbers in xenografts of Ewing's sarcoma. J. Exp. Clin. Cancer Res. 31, 24.
44. Riggi N, Suva ML, Stamenkovic I (2011) The cancer stem cell paradigm in Ewing's sarcoma: what can we learn about these rare cells from a rare tumor? Expert Rev. Anticancer Ther. 11, 143-145.
45. Riggi N, Suva ML, De Vito C, Provero P, Stehle JC, Baumer K et al. (2010) EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev. 24, 916-932.
46. Ban J, Jug G, Mestdagh P, Schwentner R, Kauer M, Aryee DN et al. (2011) Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma. Oncogene 30, 2173-2180.
47. De Vito C, Riggi N, Suva ML, Janiszewska M, Horlbeck J, Baumer K et al. (2011) Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development. PLoS One 6, e23592.
48. McKinsey EL, Parrish JK, Irwin AE, Niemeyer BF, Kern HB, Birks DK et al. (2011) A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene 30, 4910-4920.
49. Robin TP, Smith A, McKinsey E, Reaves L, Jedlicka P, Ford HL (2012) EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Mol. Cancer Res. 10, 1098-1108.
50. Nakatani F, Ferracin M, Manara MC, Ventura S, Del Monaco V, Ferrari S et al. (2012) miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J. Pathol. 226, 796-805.
51. Li J, You T, Jing J (2014) MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway. Cell Prolif. 47, 152-160.
52. Iida K, Fukushi J, Matsumoto Y, Oda Y, Takahashi Y, Fujiwara T et al. (2013) miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Cancer Cell Int. 13, 21.
53. Franzetti GA, Laud-Duval K, Bellanger D, Stern MH, Sastre-Garau X, Delattre O (2013) MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor. Oncogene 32, 3915-3921.
54. Dylla L, Jedlicka P (2013) Growth-promoting role of the miR-106a~363 cluster in Ewing sarcoma. PLoS One 8, e63032.